Vol 6, No 2S (2012)

Table of Contents

Editorial

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
Mario Annunziata
PDF
3-5

Case report

Nilotinib therapy after resistance to imatinib
Raffaele Porrini, Enrico Montefusco
PDF
7-10
Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk
Ursula Sessa, Maria Celentano, Stefano Rocco, Rossella Fabbricini, Olimpia Finizio, Vincenzo Mettivier
PDF
11-14
Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML
Giovanni Caocci, Sandra Atzeni, Giorgio La Nasa
PDF
15-18
Safety and efficacy of nilotinib after 10 years of interferon
Filippo Russo
PDF
19-22